BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 27936479)

  • 1. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma.
    Best J; Bilgi H; Heider D; Schotten C; Manka P; Bedreli S; Gorray M; Ertle J; van Grunsven LA; Dechêne A
    Z Gastroenterol; 2016 Dec; 54(12):1296-1305. PubMed ID: 27936479
    [No Abstract]   [Full Text] [Related]  

  • 2. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis.
    Best J; Bechmann LP; Sowa JP; Sydor S; Dechêne A; Pflanz K; Bedreli S; Schotten C; Geier A; Berg T; Fischer J; Vogel A; Bantel H; Weinmann A; Schattenberg JM; Huber Y; Wege H; von Felden J; Schulze K; Bettinger D; Thimme R; Sinner F; Schütte K; Weiss KH; Toyoda H; Yasuda S; Kumada T; Berhane S; Wichert M; Heider D; Gerken G; Johnson P; Canbay A
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):728-735.e4. PubMed ID: 31712073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chinese expert consensus statement on the clinical application of AFP/AFP-L3%/DCP using GALAD and GALAD-like algorithm in HCC.
    Huang C; Xiao X; Zhou L; Chen F; Wang J; Hu X; Gao C;
    J Clin Lab Anal; 2023 Dec; 37(23-24):e24990. PubMed ID: 38063322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States.
    Tayob N; Kanwal F; Alsarraj A; Hernaez R; El-Serag HB
    Clin Gastroenterol Hepatol; 2023 Feb; 21(2):415-423.e4. PubMed ID: 35124267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis.
    Singal AG; Tayob N; Mehta A; Marrero JA; El-Serag H; Jin Q; Saenz de Viteri C; Fobar A; Parikh ND
    Hepatology; 2022 Mar; 75(3):541-549. PubMed ID: 34618932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GALAD Score Detects Early-Stage Hepatocellular Carcinoma in a European Cohort of Chronic Hepatitis B and C Patients.
    Schotten C; Ostertag B; Sowa JP; Manka P; Bechmann LP; Hilgard G; Marquardt C; Wichert M; Toyoda H; Lange CM; Canbay A; Johnson P; Wedemeyer H; Best J
    Pharmaceuticals (Basel); 2021 Jul; 14(8):. PubMed ID: 34451832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of triple biomarkers AFP, AFP-L3, and PIVAKII for early detection of hepatocellular carcinoma in China: Expectation.
    Gao J; Song P
    Drug Discov Ther; 2017; 11(3):168-169. PubMed ID: 28757516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Combined Application of AFP, AFP-L3%, and DCP for Hepatocellular Carcinoma Diagnosis: A Meta-analysis.
    Wang X; Zhang Y; Yang N; He H; Tao X; Kou C; Jiang J
    Biomed Res Int; 2020; 2020():5087643. PubMed ID: 33015170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A simultaneous monitoring of Lens culinaris agglutinin A-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin as an early diagnosis of hepatocellular carcinoma in the follow-up of cirrhotic patients.
    Shimauchi Y; Tanaka M; Kuromatsu R; Ogata R; Tateishi Y; Itano S; Ono N; Yutani S; Nagamatsu H; Matsugaki S; Yamasaki S; Tanikawa K; Sata M
    Oncol Rep; 2000; 7(2):249-56. PubMed ID: 10671666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
    Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
    Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Des-γ carboxyprothrombin may not be a good biomarker for hepatocellular carcinoma in those chronically infected with hepatitis B virus with basal core promoter double mutations (T^{1762}, A^{1764}), a prospective study.
    Li GJ; Chen QY; Harrison TJ; Wang XY; Hu LP; Yang QL; Li KW; Fang ZL
    Cancer Biomark; 2017; 18(3):241-248. PubMed ID: 28085009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Des-gamma-carboxyprothrombin for early identification and prognosis of hepatocellular carcinoma--a case control study from western Nepal.
    Mittal A; Gupta SP; Sathian B; Sreedharan J; Poudel B; Yadav SK; Pandeya DR
    Asian Pac J Cancer Prev; 2012; 13(11):5773-5. PubMed ID: 23317255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone.
    Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Yamamoto M; Takasaki K; Nakano M
    J Gastroenterol Hepatol; 2002 Jul; 17(7):772-8. PubMed ID: 12121507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal Assessment of Three Serum Biomarkers to Detect Very Early-Stage Hepatocellular Carcinoma.
    Choi J; Kim GA; Han S; Lee W; Chun S; Lim YS
    Hepatology; 2019 May; 69(5):1983-1994. PubMed ID: 30153338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of GALAD score and serum biomarkers for detecting NAFLD-related HCC: a systematic review and network meta-analysis.
    Li H; Liu H; Yan LJ; Ding ZN; Zhang X; Pan GQ; Han CL; Tian BW; Tan SY; Dong ZR; Wang DX; Yan YC; Li T
    Expert Rev Gastroenterol Hepatol; 2023; 17(11):1159-1167. PubMed ID: 37929312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC.
    Yamamoto K; Imamura H; Matsuyama Y; Kume Y; Ikeda H; Norman GL; Shums Z; Aoki T; Hasegawa K; Beck Y; Sugawara Y; Kokudo N
    J Gastroenterol; 2010 Dec; 45(12):1272-82. PubMed ID: 20625772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.
    Marrero JA; Feng Z; Wang Y; Nguyen MH; Befeler AS; Roberts LR; Reddy KR; Harnois D; Llovet JM; Normolle D; Dalhgren J; Chia D; Lok AS; Wagner PD; Srivastava S; Schwartz M
    Gastroenterology; 2009 Jul; 137(1):110-8. PubMed ID: 19362088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients.
    Berhane S; Toyoda H; Tada T; Kumada T; Kagebayashi C; Satomura S; Schweitzer N; Vogel A; Manns MP; Benckert J; Berg T; Ebker M; Best J; Dechêne A; Gerken G; Schlaak JF; Weinmann A; Wörns MA; Galle P; Yeo W; Mo F; Chan SL; Reeves H; Cox T; Johnson P
    Clin Gastroenterol Hepatol; 2016 Jun; 14(6):875-886.e6. PubMed ID: 26775025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis.
    Shimizu A; Shiraki K; Ito T; Sugimoto K; Sakai T; Ohmori S; Murata K; Takase K; Tameda Y; Nakano T
    Int J Mol Med; 2002 Mar; 9(3):245-50. PubMed ID: 11836630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case-Control Study.
    Piratvisuth T; Tanwandee T; Thongsawat S; Sukeepaisarnjaroen W; Esteban JI; Bes M; Köhler B; He Y; Swiatek-de Lange M; Morgenstern D; Chan HL
    Hepatol Commun; 2022 Apr; 6(4):679-691. PubMed ID: 34796691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.